Rheumatoid Arthritis

Childhood exposure to secondhand smoke may heighten the risk of developing rheumatoid arthritis (RA) later in life, even in non-smokers, according to new research.

Exposure to secondhand smoke in childhood can lead to greater risk of rheumatoid arthritis later in life, even in non-smoking adults.

A symposium presented at the Asembia Specialty Pharmacy Summit 2018 provided pharmacists a review of guideline-based RA management strategies, along with recent trial data on new and emerging agents.

In response to the Trump Administration’s drug pricing blueprint, the American College of Rheumatology issued a set of policy principles on drug prices and access to rheumatology treatment.

Upadacitinib is currently being tested in phase 3 trials of rheumatoid arthritis, psoriatic arthritis and Crohn’s disease, and is being investigated to treat ulcerative colitis, ankylosing spondylitis, atopic dermatitis and giant cell arteritis.

Baricitinib is indicated as a monotherapy or in combination with methotrexate or other disease-modifying antirheumatic drugs for adults with moderately-to-severely active rheumatoid arthritis.

The FDA has approved baricitinib (Olumiant), a once-daily oral drug for adults with moderately-to-severely active rheumatoid arthritis.

The 2019 Benefit and Payment Parameters final rule allows states to select their own Essential Health Benefits benchmark plans.

Top news of the day from across the health care landscape.

Upadacitinib, an oral agent designed to selectively inhibit JAK1, is being studied as a once-daily therapy in rheumatoid arthritis.

Upadacitinib met primary endpoints of ACR20 and clinical remission versus placebo in treatment of moderate to severe rheumatoid arthritis.

Genetic sequencing of joint biopsies may identify which patients with rheumatoid arthritis may respond to therapy.

With the introduction of biologics such as Humira, Enbrel, and Remicade to treat RA, prescription costs have steadily increased.

Targeting an energy-related molecule could prevent the onset of autoimmune diseases.

Less serious adverse events remain a concern for patients treated for chronic diseases.

An immunomodulatory cytokine interacts with its receptors differently than other cytokines.

Investigational JAK1-selective inhibitor may reduce the symptoms of atopic dermatitis.

Treatment with upadacitinib resulted in reduced disease activity and clinical remission in patients with rheumatoid arthritis.

A look at the most popular videos on The American Journal of Pharmacy Benefits over the past year.

A review of the most popular video interviews on Specialty Pharmacy Times.

Tofacitinib (Xeljanz/Xeljanz XR) improves disease severity for patients with psoriatic arthritis.

A lack of physical activity leads to a higher risk of depression among patients with rheumatic diseases.

The type of inflammatory condition may increase the risk of liver disease, despite similar treatment.

Fully understanding a patient's genes may help physicians treat rheumatic diseases.

The efficacy and safety of an adalimumab biosimilar matched the reference products in switching studies treating plaque psoriasis and rheumatoid arthritis.

The Mediterranean diet has been found to provide significant health benefits.

Adalimumab-adbm (Cyltezo) showed equivalent safety and immunogenicity to adalimumab (Humira).

Biosimilars have yet to make a significant impact on the prescription drug market.

A significant portion of patients with rheumatoid arthritis may develop cardiovascular disease.

With the growing use of cancer immunotherapies, rheumatologists expect to see more cases of inflammatory conditions.